Dianthus Therapeutics Inc. (DNTH)

Dianthus Therapeutics Inc. (DNTH) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $4.3B; returns 1 day -2.2%, 1 week +6.5%, 1 year +130.8%.

Dianthus Therapeutics, Inc. (DNTH) is a clinical-stage biotechnology company based in New York, focused on the design and development of novel monoclonal antibodies for severe autoimmune and inflammatory diseases. The company's business model revolves entirely around the advancement of its drug pipeline, with its primary product candidate being DNTH103.

Groups DNTH belongs to

• Biotechnology
• Clinical Stage Biotech
• Biopharmaceutical
• Autoimmune Diseases
• Monoclonal Antibodies
• Healthcare
• Clinical Stage
• Chronic Inflammatory Diseases
• Antibody Therapeutics
• Life Sciences

DNTH financial model: income statement, cash flow and balance sheet